Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$12M Sell
93,181
-1,267
-1% -$148K 7.95% 1
2026
Q1
$11.4M Sell
94,448
-1,350
-1% -$156K 7.73% 2
2025
Q4
$10.1M Buy
95,798
+830
+0.9% +$77.9K 7.3% 1
2025
Q3
$7.97M Buy
94,968
+992
+1% +$81.7K 6.36% 3
2025
Q2
$7.44M Sell
93,976
-3,206
-3% -$255K 5.99% 4
2025
Q1
$8.72M Sell
97,182
-580
-0.6% -$54.2K 6.5% 2
2024
Q4
$9.73M Sell
97,762
-1,784
-2% -$184K 8% 1
2024
Q3
$11.3M Sell
99,546
-5,075
-5% -$603K 4.55% 4
2024
Q2
$13M Sell
104,621
-727
-0.7% -$93.6K 9.64% 1
2024
Q1
$13.9M Sell
105,348
-250
-0.2% -$30.8K 10.32% 1
2023
Q4
$11.5M Sell
105,598
-390
-0.4% -$40.5K 10.1% 1
2023
Q3
$10.9M Sell
105,988
-871
-0.8% -$93.9K 9.5% 1
2023
Q2
$12.3M Sell
106,859
-526
-0.5% -$59.7K 8.95% 2
2023
Q1
$11.4M Sell
107,385
-23,158
-18% -$2.5M 9.48% 1
2022
Q4
$14.5M Buy
+130,543
New +$13.3M 9.34% 1

Other funds holding MRK

Slocum, Gordon & Co's MRK Position: Q2 2026 in Review

Slocum, Gordon & Co reduced its Merck (MRK) stake by 1.3% in Q2 2026, selling an estimated $148K and leaving 93,181 shares worth $12M. The position accounts for 7.95% of the portfolio, ranked #1.

Slocum, Gordon & Co first reported a position in MRK in Q4 2022 and has held it in 15 quarters since. The position peaked at $14.5M in Q4 2022. 1,533 funds tracked by Wall St. Rank hold MRK as of Q2 2026.

  • Slocum, Gordon & Co held 93,181 shares of Merck worth $12M as of Q2 2026.
  • Slocum, Gordon & Co sold 1,267 Merck shares in Q2 2026, an estimated $148K.
  • Merck made up 7.95% of Slocum, Gordon & Co's portfolio in Q2 2026, its #1 holding.
  • Slocum, Gordon & Co first reported a position in Merck in Q4 2022 and has held it in 15 quarters since.
  • Slocum, Gordon & Co's Merck position peaked at $14.5M in Q4 2022.
  • 1,533 funds tracked by Wall St. Rank held Merck as of Q2 2026.

Based on Slocum, Gordon & Co's 13F filing for Q2 2026, filed 23 Jul 2026.